BNP Paribas Financial Markets Sells 90,901 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

BNP Paribas Financial Markets lessened its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 78.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 24,390 shares of the biopharmaceutical company’s stock after selling 90,901 shares during the quarter. BNP Paribas Financial Markets’ holdings in Revance Therapeutics were worth $127,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Certuity LLC purchased a new position in Revance Therapeutics during the second quarter valued at $26,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Revance Therapeutics in the second quarter worth approximately $33,000. Hsbc Holdings PLC purchased a new stake in shares of Revance Therapeutics during the second quarter valued at approximately $38,000. Nisa Investment Advisors LLC increased its position in shares of Revance Therapeutics by 2,167.5% during the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 18,077 shares in the last quarter. Finally, Creative Planning purchased a new position in Revance Therapeutics in the 3rd quarter worth approximately $56,000. Institutional investors own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Revance Therapeutics in a report on Thursday, December 12th. They set a “hold” rating on the stock. Barclays reaffirmed an “equal weight” rating and issued a $7.00 target price (down previously from $10.00) on shares of Revance Therapeutics in a research report on Friday, September 13th. Mizuho lowered their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. HC Wainwright reaffirmed a “neutral” rating and issued a $6.60 price objective on shares of Revance Therapeutics in a report on Friday, November 8th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a report on Friday, November 8th. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $8.96.

Revance Therapeutics Stock Performance

RVNC stock opened at $3.07 on Thursday. The firm has a 50-day simple moving average of $4.43 and a two-hundred day simple moving average of $4.48. Revance Therapeutics, Inc. has a one year low of $2.30 and a one year high of $9.74. The firm has a market cap of $322.05 million, a price-to-earnings ratio of -1.59 and a beta of 0.81.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The business had revenue of $59.88 million during the quarter, compared to the consensus estimate of $67.73 million. As a group, equities analysts predict that Revance Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.